# A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)

> **NCT03535194** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 1484 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Mirikizumab
- **DRUG:** Placebo
- **DRUG:** Secukinumab

## Key facts

- **NCT ID:** NCT03535194
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-26
- **Primary completion:** 2020-03-05
- **Final completion:** 2020-06-03
- **Target enrollment:** 1484 (ACTUAL)
- **Last updated:** 2021-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03535194

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03535194, "A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03535194. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*